# CLINICAL PHARMACOLOGY and THERAPEUTICS


**Editor**

Walter Modell, M.D.

**Editorial Board**

Alvito P. Alvares, Ph.D.
Wilbert S. Aronow, M.D.
Arthur J. Atkinson, Jr., M.D.
Daniel L. Azarnoff, M.D.
Frank M. Berger, M.D., D.Sc.
Karl H. Beyer, Jr., M.D., Ph.D.
Hylan A. Bickerman, M.D.
Edward A. Carr, Jr., M.D.
Leighton E. Cluff, M.D.
Allan H. Conney, Ph.D.
T. S. Danowski, M.D.
Arthur C. DeGraff, M.D.
Peter Dineen, M.D.
Edward F. Domino, M.D.
Alvan R. Feinstein, M.D.
Vladimir Fencl, M.D.
Max Fink, M.D.
Robert B. Forney, Ph.D.
Emil Frei, III, M.D.
Milo Gibaldi, Ph.D.
Norton J. Greenberger, M.D.
Franz Gross, M.D.
Arthur Hull Hayes, Jr., M.D.
Leo E. Hollister, M.D.
Bartholomet P. Hsi, Ph.D.
Murray E. Jarvik, M.D.
Ernest Jawetz, M.D., Ph.D.
Stanley A. Kaplan, Ph.D.
Attallah Kappas, M.D.
Arthur S. Keats, M.D.
Richard H. Kessler, M.D.
Kenneth G. Kohlstaedt, M.D.
Louis Lasagna, M.D.
Louis Lemberger, M.D., Ph.D.
Gerhard Levy, Pharm.D.
T. A. Loomis, M.D., Ph.D.
David T. Lowenthal, M.D.
Daniel S. Lukas, M.D.
Dean T. Mason, M.D.
Fletcher H. McDowell, M.D.
Arno G. Motulsky, M.D.
Marcus M. Reidenberg, M.D.
R. K. Richards, M.D.
David G. Shand, M.B., Ph.D.
Jay Tepperman, M.D.
Max Tishler, Ph.D.
Leroy D. Vandam, M.D.
Elliot S. Vesell, M.D.
Louis Weinstein, M.D.
John G. Wagner, Ph.D.
E. Leong Way, Ph.D.



**Volume 25, January-June, 1979**
**The C. V. Mosby Company, St. Louis**

Volume 25
Copyright © 1979 by
The C. V. Mosby Company

*All rights reserved*

*Printed in the United States of America*

# Index to volume 25

## Author index


*A*

Abbott JA: *see* Rogers et al, 469
Aboras NE: *see* Safar et al, 266
Agras WS, Marshall G: Recruitment for the Coronary Primary Prevention Trial, 688
Ahmed M: *see* Gault et al, 499
Aldridge A, Aranda JV, Neims AH: Caffeine metabolism in the newborn, 447
Alexander F: *see* Dubb et al, 699
Allen JC: *see* Bean and Allen, 199
Alván G: *see* Arvidsson et al, 732
Amsterdam JD: *see* Brunswick et al, 605
Anderson KE: *see* Pantuck et al, 88
Anderson SA: *see* Brater et al, 435
Anderton RC: *see* Ruffin et al, 536
Aranda JV: *see* Aldridge et al, 447
Aronow WS, Van Camp S, Turbow M, Whittaker K, Lurie M: Acebutolol in supraventricular arrhythmias, 149
— *see* Danahy et al, 541
Arvidsson A, Borgå O, Alván G: Renal excretion of cephapirin and cephaloridine: Evidence for saturable tubular reabsorption, 732
Åström H: *see* Collste et al, 416
Atkinson AJ Jr: *see* Lertora et al, 273

*B*

Bachman J: *see* Benowitz et al, 440
Bachmann K, Shapiro R, Fulton R, Carroll FT, Sullivan TJ: Smoking and warfarin disposition, 309
Ball R: *see* Jaillon et al, 652
Balster RL: *see* Griffiths and Balster, 611
Bayne L: *see* Nattel et al, 96
Beam TR Jr, Allen JC: Assessment of antibiotic efficacy in acute bacterial meningitis, 199
Becker CE: *see* Pond et al, 694
Bedikian AY: *see* Hall et al, 82
Bell R: *see* Mason et al, 408
Benedict GW: LRC Coronary Prevention Trial: Baltimore, 685
Benjamin RS: *see* Hall et al, 82
Benowitz NL, Rosenberg J, Rogers W, Bachman J, Jones RT: Cardiovascular effects of intravenous delta-9-tetrahydrocannabinol: Autonomic nervous mechanisms, 440
— *see* Pond et al, 694
— *see* Rogers et al, 469
Berger J-P: *see* Blanc et al, 493
Bergkvist Y: *see* Frisk-Holmberg et al, 345
Bhargava RNK: *see* Kalamegham et al, 67
Blair AD: *see* Cutler et al, 514
Blanc S, Leuenberger P, Berger J-P, Brooke EM, Schelling J-L: Judgments of trained observers on adverse drug reactions, 493
Blanke RV: *see* Boylan et al, 579
Blaschke T: *see* Jaillon et al, 652
Bochner F: *see* Tanner et al, 571
Boer P: *see* Teeuw et al, 294
Bojsen J: *see* Kølendorf et al, 598
Borg K-O: *see* Collste et al, 416
— *see* Collste et al, 423
Borgå O: *see* Arvidsson et al, 732
Bourne DW: *see* McAllister et al, 1
Boylan JJ, Cohn WJ, Egle JL Jr, Blanke RV, Guzelian PS: Excretion of chlordecone by the gastrointestinal tract: Evidence for a nonbiliary mechanism, 579
Branson R: *see* Fletcher et al, 742
Brater DC: Effect of indomethacin on salt and water homeostasis, 322
— Renal sites of action of azosemide, 428
—, Anderson SA, Strowig S: Azosemide, a "loop" diuretic, and furosemide, 435
Bravo EL: *see* Cody et al, 662
— *See* Wollam et al, 675
Brien JF, Peachey JE, Loomis CW, Rogers BJ: The calcium carbimide–ethanol interaction: Effects of ethanol dose, 454
Bromley PA: *see* Müller et al, 528
Brooke EM: *see* Blanc et al, 493
Brunswick DJ, Amsterdam JD, Mendels J, Stern SL: Prediction of steady-state imipramine and desmethylimipramine plasma concentrations from single-dose data, 605
Bull JM: *see* Gormley et al, 351
Busto U: *see* Naranjo et al, 154



January, pp. 1-130; February, pp. 131-256; March, pp. 257-380; April, pp. 381-492; May (Part 1), pp. 493-628; May (Part 2), pp. 629-766; June, pp. 767-896.

*C*

Caffin J: *see* Tanner et al, 571
Calabrese LH: *see* Cody et al, 662
Canner PL: Responses, 657
— *see* Klimt and Canner, 641
Carroll FT: *see* Bachmann et al, 309
Chadwick M: *see* McKelvey et al, 586
Chalmers TC: Invited remarks, 649
Chen Z: *see* Danon and Chen, 316
Chetty K: *see* Danahy et al, 541
Chiou WL, Pu FS: Saliva levels of endogenous "true" creatinine in normal subjects, 639
Ciaccio EI, Fruncillo RJ: Urinary excretion of D-glucaric acid by severely burned patients, 340
Clough JD: *see* Cody et al, 662
Cody RJ Jr, Calabrese LH, Clough JD, Tarazi RC, Bravo EL: Development of antinuclear antibodies during acebutolol therapy, 662
— *see* Wollam et al, 675
Cohen I: *see* Mason et al, 408
Cohn WJ: *see* Boylan et al, 579
Collste P, Borg K-O, Åström H, von Bahr C: Contribution of 4-hydroxy-alprenolol to adrenergic beta receptor blockade of alprenolol, 416
—, Seideman P, Borg K-O, Haglund K, von Bahr C: Influence of pentobarbital on effect and plasma levels of alprenolol and 4-hydroxy-alprenolol, 423
Conney AH: *see* Pantuck et al, 88
Croke G: Recruitment for the National Cooperative Gallstone Study, 691
Cupano J: *see* Garland et al, 706
Cusack B, Kelly J, O'Malley K, Noel J, Lavan J, Horgan J: Digoxin in the elderly: Pharmacokinetic consequences of old age, 634
Cutler RE, Blair AD, Kelly MR: Cefadroxil kinetics in patients with renal insufficiency, 514
Cysyk R: *see* Gormley et al, 351

*D*

Danahy DT, Tobis JM, Aronow WS, Chetty K, Glauser F: Effects of isosorbide dinitrate on pulmonary hypertension in chronic obstructive pulmonary disease, 541
Danon A, Chen Z: Binding of imipramine to plasma proteins: Effect of hyperlipoproteinemia, 316
Davis JD, Struth AG, Turner RA, Pisko EJ, Ruchte IR: Pirprofen and aspirin in the treatment of rheumatoid arthritis, 618
De Guzman M: *see* Venkataraman et al, 43
Desmond RV: *see* Roberts et al, 688
Domeij-Nyberg B: *see* Frisk-Holmberg et al, 345
Dubb JW, Stote RM, Alexander F, Intoccia AP, Geczy M, Pendleton RG: Studies with a PNMT inhibitor, 699
Durairaj SK: *see* Venkataraman et al, 43
Du Souich P, Lalka D, Slaughter R, Elvin AT, McLean AJ: Mechanisms of nonlinear disposition kinetics of sulfamethazine, 172
— *see* McLean et al, 161

*E*

Ebbutt A: *see* Kubik et al, 25
Ederer F: Introduction, 699
— *see* Ferris and Ederer, 720
Egle JL Jr: *see* Boylan et al, 579
Ehrnebo M: *see* Ehrsson et al, 167
— *see* Swanbeck et al, 478
Ehrsson H, Nilsson S-O, Ehrnebo M, Wallin I, Wennersten G: Effect of food on kinetics of 8-methoxsalen, 167
— *see* Swanbeck et al, 478
Eiben C: *see* Tallarida et al, 381
Elvin AT: *see* du Souich et al, 172
Erickson JL: *see* McAllister et al, 1
Evans JT: Internal monitoring: Patient and study management at the clinic, 712

*F*

Fann WE: *see* Garland et al, 706
Feinstein AR: Clinical biostatistics. XLVI. What are the criteria for criteria? 108
— Clinical biostatistics. XLVII. Scientific standards vs. statistical associations and biologic logic in the analysis of causation, 481
Ferris FL, Ederer F: External monitoring in multiclinic trials: Applications from ophthalmologic studies, 720
Field B, Lu C, Hepner GW: Inhibition of hepatic drug metabolism by norethindrone, 196
Fletcher JC, Branson R, Freireich EJ: Invited remarks, 742
Fleuren HLJ, Verwey-van Wissen C, van Rossum JM: Dose-dependent urinary excretion of chlorthalidone, 668
Freireich EJ: *see* Fletcher et al, 742
Frisk-Holmberg M, Bergkvist Y, Domeij-Nyberg B, Hellström L, Jansson F: Chloroquine serum concentration and side effects: Evidence for dose-dependent kinetics, 345
Frith PA: *see* Ruffin et al, 536
Frost GW: *see* Stokes et al, 645
Fruncillo RJ: *see* Ciaccio and Fruncillo, 340
Fulton R: *see* Bachmann et al, 309

*G*

Galinsky RE: *see* Pond et al, 694
Garland WA, Muccino RR, Min BH, Cupano J, Fann WE: A method for the determination of amitriptyline and its metabolities nortriptyline, 10-hydroxyamitriptyline, and 10-hydroxynortriptyline in human plasma using stable isotope dilution and gas chromatography–chemical ionization mass spectrometry (GC-CIMS), 706
— *see* Pantuck et al, 88

Gault MH, Sugden D, Maloney C, Ahmed M, Tweeddale M: Biotransformation and elimination of digoxin with normal and minimal renal function, 499
Geczy M: *see* Dubb et al, 699
Georges DR: *see* Weiss et al, 283
Gerlag PGG: *see* Thien et al, 657
Geyskes GG: *see* Teeuw et al, 294
Gibaldi M: *see* McLean et al, 161
Glauser F: *see* Danahy et al, 541
Gold CH, Viljoen M: Site of renal action of xipamide, 522
González G: *see* Naranjo et al, 154
Gordon RS Jr: Introduction, 661
Gormley PE, Bull JM, LeRoy AF, Cysyk R: Kinetics of *cis*-dichlorodiammineplatinum, 351
Graham RM: *see* Stokes et al, 645
Griffiths RR, Balster RL: Opioids: Similarity between evaluations of subjective effects and animal self-administration results, 611
Guzelian PS: *see* Boylan et al, 579

*H*

Haglund K: *see* Collste et al, 423
Hall SW, Yeung K, Benjamin RS, Stewart D, Valdivieso M, Bedikian AY, Loo TL: Kinetics of gallium nitrate, a new anticancer agent, 82
Halliday J: *see* Tanner et al, 571
Ham J: *see* Sheiner et al 358
Hamilton MT: Invited remarks, 647
Hargreave FE: *see* Ruffin et al, 536
Harrison D: *see* Jaillon et al, 652
Hawkins BS: *see* Meinert and Hawkins, 754
Haywood LJ: *see* Venkataraman et al, 43
Hellström L: *see* Frisk-Holmberg et al, 345
Hepner GW: *see* Field et al, 196
Hollifield JW: *see* Vestal et al, 19
Hope-Gill HF: *see* Myers and Hope-Gill, 303
Horgan J: *see* Cusack et al, 634
Hundt HKL: *see* Müller et al, 528
Huysmans FTM: *see* Thien et al, 657

*I*

Inaba T: *see* Stewart et al, 464
Intoccia AP: *see* Dubb et al, 699
Itskovitz HD: *see* Kochar et al, 143

*J*

Jaillon P, Rubin P, Yee Y-G, Ball R, Kates R, Harrison D, Blaschke T: Influence of congestive heart failure on prazosin kinetics, 652
Jain A, McMahon FG, Slattery JT, Levy G: Effect of naproxen on the steady-state serum concentration and anticoagulant activity of warfarin, 61
— *see* Slattery et al, 51
Jansson F: *see* Frisk-Holmberg et al, 345
John V: *see* Kubik et al, 25
Jones C: *see* Lertora et al, 273
Jones RT: *see* Benowitz et al, 440
Jonsson L: *see* Swanbeck et al, 478
Jounela AJ: *see* Lilja et al, 726
Juustila H: *see* Lilja et al, 726

*K*

Kahn HA: Diagnostic standardization, 703
Kalamegham R, Krishnaswamy K, Krishnamurthy S, Bhargava RNK: Metabolism of drugs and carcinogens in man: Antipyrine elimination as an indicator, 67
Kalow W: *see* Stewart et al, 464
Kappas A: *see* Pantuck et al, 88
Karlberg BE, Nilsson O, Tolagen K, Nitelius E, Waern U: Once-daily metoprolol in primary hypertension, 399
Kates R: *see* Jaillon et al, 652
Kelly J: *see* Cusack et al, 634
Kelly MR: *see* Cutler et al, 514
Kendall M: *see* Kubik et al, 25
Kessler KM, Leech RC, Spann JF: Blood collection techniques, heparin and quinidine protein binding, 204
Khalil SA: *see* Naggar and Khalil, 719
Kheder MA: *see* Safar et al, 266
Kirchhof B: *see* Ohnhaus et al, 591
Klimt CR, Canner PL: Terminating a long-term clinical trial, 641
— *see* Meier and Klimt, 655
Kochak G: *see* Mason et al, 408
Kochar MS, Zeller JR, Itskovitz HD: Prazosin in hypertension with and without methyldopa, 143
Koene RAP: *see* Thien et al, 657
Kølendorf K, Bojsen J, Nielsen SL: Adipose tissue blood flow and insulin disappearance from subcutaneous tissue, 598
Kornhauser DM: *see* Vestal et al, 19
Krishnamurthy S: *see* Kalamegham et al, 67
Krishnaswamy K: *see* Kalamegham et al, 67
Kubik M, Kendall M, Ebbutt A, John V: Metoprolol with and without chlorthalidone in hypertension, 25
Kumana CR: *see* Ruffin et al, 536
Kushner W: *see* Lertora et al, 273

*L*

Lachenbruch PA: Invited remarks, 724
Lake CR: *see* Ziegler et al, 137
Lalka D: *see* du Souich et al, 172
Lasagna L: Problems in publication of clinical trial methodology, 751
— *see* Sundaresan et al, 391
Lavan J: *see* Cusack et al, 634
Lavene DL: *see* Weiss et al, 283
Lebacqz K: *see* Levine and Lebacqz, 728
Lee W-K: *see* Lertora et al, 273
Leech RC: *see* Kessler et al, 204
Leenen FHH: *see* Teeuw et al, 294
LeRoy AF: *see* Gormley et al, 351

Lertora JJL, Atkinson AJ Jr, Kushner W, Nevin MJ, Lee W-K, Jones C, Schmid FR: Long-term antiarrhythmic therapy with *N*-acetylprocainamide, 273
Leuenberger P: *see* Blanc et al, 493
Levenson JA: *see* Safar et al, 266
Levine RJ, Lebacqz K: Some ethical considerations in clinical trials, 728
Levy G: *see* Jain et al, 61
— *see* Slattery and Levy, 184
— *see* Slattery et al, 51
Levy RJ, Lian JB: γ-Carboxyglutamate excretion and warfarin therapy, 562
Lian JB: *see* Levy and Lian, 562
Lilja M, Jounela AJ, Juustila H, Marvola M: Antihypertensive effects of clonidine, 726
Lomedico M: *see* McKelvey et al, 586
London GM: *see* Safar et al, 266
Loo TL: *see* Hall et al, 82
— *see* McKelvey et al, 586
Loomis CW: *see* Brien et al, 454
Loria Y: *see* Weiss et al, 283
Lu C: *see* Field et al, 196
Lu K: *see* McKelvey et al, 586
Lucassen M: *see* Stewart et al, 464
Lunell N-O: *see* Tomson et al, 74
Lurie M: *see* Aronow et al, 149

*M*

MacCarthy EP: *see* Stokes et al, 645
Maloney C: *see* Gault et al, 499
Marshall G: *see* Agras and Marshall, 688
Marvola M: *see* Lilja et al, 726
Mason WD, Winer N, Kochak G, Cohen I, Bell R: Kinetics and absolute bioavailability of atenolol, 408
Matsukura S, Sakamoto N, Seino Y, Tamada T, Matsuyama H, Muranaka H: Cotinine excretion and daily cigarette smoking in habituated smokers, 555
—, —, Takahashi K, Matsuyama H, Muranaka H: Effect of pH and urine flow on urinary nicotine excretion after smoking cigarettes, 549
Matsuyama H: *See* Matsukura et al, 549
— *see* Matsukura et al, 555
McAllister RG Jr, Bourne DW, Tan TG, Erickson JL, Wachtel CC, Todd EP: Effects of hypothermia on propranolol kinetics, I
McAvoy TJ: The biologic half-life of heparin, 372
McKelvey EM, Lomedico M, Lu K, Chadwick M, Loo TL: Dichloroallyl lawsone, 586
McLean A, du Souich P, Gibaldi M: Noninvasive kinetic approach to the estimation of total heparin blood flow and shunting in chronic liver disease—a hypothesis, 161
McLean AJ: *see* du Souich et al, 172
McMahon FG: *see* Jain et al, 61
— *see* Slattery et al, 51
Meier P: Terminating a clinical trial—the ethical problem, 633
—, Klimt CR: Responses, 655
Meinert CL: Introduction, 632
—, Hawkins BS: Methodology: The case for improved communications, 754
Mendels J: *see* Brunswick et al, 605
Miller RD: *see* Sheiner et al, 358
Milliez PL: *see* Weiss et al, 283
Min BH: *see* Garland et al, 706
— *see* Pantuck et al, 88
Montgomery JM: *see* Ruffin et al, 683
Mosteller F: Problems of omission in communications, 761
Moulding TS: The unrealized potential of the medication monitor, 131
Mowery RL, Williams OD: Aspects of clinic monitoring in large-scale multiclinic trials, 717
Muccino RR: *see* Garland et al, 706
Müller FO, Hundt HKL, Bromley PA, Torres J, Vanderbeke O: Single and divided doses of penbutolol, 528
Muranaka H: *see* Matsukura et al, 549
— *see* Matsukura et al, 555
Murray RB: *see* Tallarida et al, 381
Myers MG, Hope-Gill HF: Effect of *d*- and *dl*-propranolol on glucose-stimulated insulin release, 303

*N*

Naggar VF, Khalil SA: Effect of magnesium trisilicate on nitrofurantoin absorption, 719
Naranjo CA, Pontigo E, Valdenegro C, González G, Ruiz I, Busto U: Furosemide-induced adverse reactions in cirrhosis of the liver, 154
Nattel S, Bayne L, Ruedy J: Physostigmine in coma due to drug overdose, 96
Neims AH: *see* Aldridge et al, 447
Nevin MJ: *see* Lertora et al, 273
Newhouse MT: *see* Ruffin et al, 536, 683
Nielsen SL: *see* Kølendorf et al, 598
Nilsson O: *see* Karlberg et al, 399
Nilsson S-O: *see* Ehrsson et al, 167
Nitelius E: *see* Karlberg et al, 399
Noel J: *see* Cusack et al, 634

*O*

Ohnhaus EE, Kirchhof B, Peheim E: Effect of enzyme induction on plasma lipids using antipyrine, phenobarbital, and rifampicin, 591
O'Malley K: *see* Cusack et al, 634
Osifo NG: Drug-related transient dyskinesias, 767

*P*

Pantuck CB: *see* Pantuck et al, 88
Pantuck EJ, Pantuck CB, Garland WA, Min BH, Wattenberg LW, Anderson KE, Kappas A, Conney AH: Stimulatory effect of brussels sprouts and cabbage on human drug metabolism, 88
Peachey JE: *see* Brien et al, 454
Peheim E: *see* Ohnhaus et al, 591
Pendleton RG: *see* Dubb et al, 699

Phillips M: *see* Pond et al, 694
Pisko EJ: *see* Davis et al, 618
Pond SM, Phillips M, Benowitz NL, Galinsky RE, Tong TG, Becker CE: Diazepam kinetics in acute alcohol withdrawal, 694
Pontigo E: *see* Naranjo et al, 154
Powell L: *see* Tanner et al, 571
Prout T: Introduction, 679
Prout TE: Other examples of recruitment problems and solutions, 695
Pu FS: *see* Chiou and Pu, 639
Puschett JB: *see* Teredesai and Puschett, 331

*R*

Rane A: *see* Tomson et al, 74
Relman AS: Publications and promotions for the clinical investigator, 673
Remington RD: Problems of university-based scientists associated with clinical trials, 662
Roberts RK, Desmond PV, Wilkinson GR, Schenker S: Disposition of chlordiazepoxide: Sex differences and effects of oral contraceptives, 688
Rogers BJ: *see* Brien et al, 454
Rogers WK, Benowitz NL, Wilson KM, Abbott JA: Effect of disulfiram on adrenergic function, 469
— *see* Benowitz et al, 440
Rosenberg J: *see* Benowitz et al, 440
Roth HP: Introduction, 750
Rubin P: *see* Jaillon et al, 652
Ruchte IR: *see* Davis et al, 618
Rudd P: Medication packaging: Simple solutions to nonadherence problems? 257
Ruedy J: *see* Nattel et al, 96
Ruffin RE, Frith PA, Anderton RC, Kumana CR, Newhouse MT, Hargreave FE: Selectivity of beta adrenoreceptor antagonist drugs assessed by histamine bronchial provocation, 536
—, Montgomery JM, Newhouse MT: Aerosol fenoterol by intermittent positive pressure breathing in asthmatic patients, 683
Ruiz I: *see* Naranjo et al, 154

*S*

Safar ME, London GM, Levenson JA, Kheder MA, Aboras NE, Simon ACh: Effect of alphamethyldopa on cardiac output in hypertension, 266
— *see* Weiss et al, 283
Sakamoto N: *see* Matsukura et al, 549
— *see* Matsukura et al, 555
Schelling J-L: *see* Blanc et al, 493
Schenker S: *see* Roberts et al, 688
Schmid FR: *see* Lertora et al, 273
Schoenberger JA: Recruitment in the Coronary Drug Project and the Aspirin Myocardial Infarction Study, 681
Schoolman HM: Retrieving information on clinical trial methodology, 758
Schrijver G, Weinberger MH: Hydrochlorothiazide and spironolactone in hypertension, 33
Seideman P: *see* Collste et al, 423
Seino Y: *see* Matsukura et al, 555
Shand DG: *see* Vestal et al, 19
— *see* Wood et al, 103
Shapiro R: *see* Bachmann et al, 309
Sheiner LB, Stanski DR, Vozeh S, Miller RD, Ham J: Simultaneous modeling of pharmacokinetics and pharmacodynamics: Application to *d*-tubocurarine, 358
Shoulson I: *see* Ziegler et al, 137
Silvers A: Invited remarks, 725
— *see* Safar et al, 266
— *see* Weiss et al, 283
Slattery JT, Levy G: Acetaminophen kinetics in acutely poisoned patients, 184
—, —, Jain A, McMahon FG: Effect of naproxen on the kinetics of elimination and anticoagulant activity of a single dose of warfarin, 51
— *see* Jain et al, 61
Slaughter R: *see* du Souich et al, 172
Spann JF: *see* Kessler et al, 204
Stamler J: Effective clinical trials investigators and adequate incentives, 666
— Invited remarks, 651
Stamler R: Appendix 1: A proposed mechanism and set of criteria for the evaluation of the scientific contribution of individual investigators in collaborative studies, including large clinical trials, 671
Stanski DR: *see* Sheiner et al, 358
Steinberg SM: *see* Warren et al, 624
Steinsland O: *see* Ziegler et al, 137
Stern SL: *see* Brunswick et al, 605
Stewart D: *See* Hall et al, 82
Stewart DJ, Inaba T, Lucassen M, Kalow W: Cocaine metabolism: Cocaine and norcocaine hydrolysis by liver and serum esterases, 464
Stokes GS, Frost GW, Graham RM, MacCarthy EP: Indoramin and prazosin as adjuncts to beta adrenoreceptor blockade in hypertension, 645
Stote RM: *see* Dubb et al, 699
Strowig S: *see* Brater et al, 435
Struth AG: *see* Davis et al, 618
Sugden D: *see* Gault et al, 499
Sullivan TJ: *see* Bachmann et al, 309
Sundaresan PR, Wardell WM, Weintraub M, LaSagna L: Methodology for demonstrating sustained efficacy of hypnotics: A comparative study of triazolam and flurazepam, 391
Sundwall A: *see* Tomson et al, 74
Swanbeck G, Ehrsson H, Ehrnebo M, Wallin I, Jonsson L: Serum concentration and phototoxic effect of methoxsalen in patients with psoriasis, 478
Swerdlin ARH: *see* Warren et al, 624

*T*

Takahashi K: *see* Matsukura et al, 549
Tallarida RJ, Murray RB, Eiben C: A scale for assessing the severity of diseases and adverse drug reactions, 381
Tamada T: *see* Matsukura et al, 555
Tan TG: *see* McAllister et al, 1
Tanner A, Bochner F, Caffin J, Halliday J, Powell L: Dose-dependent prednisolone kinetics, 571
Tarazi RC: *see* Cody et al, 662
— *see* Wollam et al, 675
Teeuw AH, Leenen FHH, Geyskes GG, Boer P: Atenolol and chlorthalidone on blood pressure, heart rate, and plasma renin activity in hypertension, 294
Teredesai P, Puschett JB: Acute effects of piretanide in normal subjects, 331
Teychenne PF: *see* Ziegler et al, 137
Thien TA, Huysmans FTM, Gerlag PGG, Koene RAP, Wijdeveld PGAB: Diazoxide infusion in severe hypertension and hypertensive crisis, 657
Tobis JM: *see* Danahy et al, 541
Todd EP: *see* McAllister et al, 1
Tolagen K: *see* Karlberg et al, 399
Tomson G, Lunell N-O, Sundwall A, Rane A: Placental passage of oxazepam and its metabolism in mother and newborn, 74
Tong TG: *see* Pond et al, 694
Torres J: *see* Müller et al, 528
Turbow M: *see* Aronow et al, 149
Turner RA: *see* Davis et al, 618
Tweeddale M: *see* Gault et al, 499

*V*

Valdenegro C: *see* Naranjo et al, 154
Valdivieso M: *see* Hall et al, 82
Van Camp S: *see* Aronow et al, 149
Vanderbeke O: *see* Müller et al, 528
Van Rossum JM: *see* Fleuren et al, 668
Venkataraman K, Durairaj SK, de Guzman M, Haywood LJ: Isosorbide dinitrate in acute and chronic heart failure, 43
Verwey-van Wissen C: *see* Fleuren et al, 668
Vestal RE, Kornhauser DM, Hollifield JW, Shand DG: Inhibition of propranolol metabolism by chlorpromazine, 19
Viljoen M: *see* Gold and Viljoen, 522
Von Bahr C: *see* Collste et al, 416
— *see* Collste et al, 423
Vozeh S: *see* Sheiner et al, 358

*W*

Waal-Manning HJ: Atenolol and three nonselective $\beta$-blockers in hypertension, 8
Wachtel CC: *see* McAllister et al, 1
Waern U: *see* Karlberg et al, 399
Wallin I: *see* Ehrsson et al, 167
— *see* Swanbeck et al, 478
Wardell WM: *see* Sundaresan et al, 391
Warren SE, Swerdlin ARH, Steinberg SM: Treatment of alkalosis with ammonium chloride: A case report, 624
Wattenberg LW: *see* Pantuck et al, 88
Weinberger MH: *see* Schrijver and Weinberger, 33
Weintraub M: *see* Sundaresan et al, 391
Weiss YA, Lavene DL, Safar ME, Simon ACh, Loria Y, Georges DR, Milliez PL: Guanfacine kinetics in patients with hypertension, 283
Wennersten G: *see* Ehrsson et al, 167
Whittaker K: *see* Aronow et al, 149
Wijdeveld PGAB: *see* Thien et al, 657
Wilkinson GR: *see* Roberts et al, 688
Williams AC: *see* Ziegler et al, 137
Williams OD: A framework for the quality assurance of clinical data, 700
— *see* Mowery and Williams, 717
Wilson KM: *see* Rogers et al, 469
Winer N: *see* Mason et al, 408
Wollam GL, Cody RJ Jr, Tarazi RC, Bravo EL: Acute hemodynamic effects and cardioselectivity of acebutolol, practolol, and propranolol, 675
Wood AJJ: *see* Wood et al, 103
Wood M, Shand DG, Wood AJJ: Altered drug binding due to the use of indwelling heparinized cannulas (heparin lock) for sampling, 103

*Y*

Yee Y-G: *see* Jaillon et al, 652
Yeung K: *see* Hall et al, 82

*Z*

Zeller JR: *see* Kochar et al, 143
Ziegler MG, Lake CR, Williams AC, Teychenne PF, Shoulson I, Steinsland O: Bromocriptine inhibits norepinephrine release, 137

## Subject index


*A*

Abuse potential of drugs in man, use of animals to investigate (Griffiths and Balster), 611
Acebutolol, practolol, and propranolol, acute hemodynamic effects and cardioselectivity of (Wollam et al), 813
in supraventricular arrhythmias (Aronow et al), 149
therapy, development of antinuclear antibodies during (Cody et al), 800
Acetaminophen kinetics in acutely poisoned patients (Slattery and Levy), 184
*N*-Acetylprocainamide, long-term antiarrhythmic therapy with (Lertora et al), 273
Adrenergic function, effect of disulfiram on (Rogers et al), 469
Alcohol withdrawal, acute, diazepam kinetics in (Pond et al), 832
Alcoholism, calcium carbimide in treatment of (Brien et al), 454
Alkalosis, treatment of, with ammonium chloride; case report (Warren et al), 624
Alpha adrenoreceptor blocker with preexisting beta adrenoreceptor blockade in hypertension (Stokes et al), 645
-methyldopa, effect of, on cardiac output in hypertension (Safar et al), 266
Alprenolol, adrenergic beta receptor blockade of, contribution of 4-hydroxy-alprenolol to (Collste et al), 416
and 4-hydroxy-alprenolol, effect and plasma levels of, influence of pentobarbital on (Collste et al), 423
American Society for Clinical Pharmacology and Therapeutics, abstracts of papers, Eightieth Annual Meeting, March 21-23, 1979, Crown Center Hotel, Kansas City, Mo., 211
meeting program of, Eightieth Annual Meeting, March 21-23, 1979, Crown Center Hotel, Kansas City, Mo., 118
message from president of—come to Kansas City March 21-23, 1979, 117
notes of, 380, 492, 877
Aminopyrine, depressive effects of norethindrone on hepatic drug metabolism of (Field et al), 196
Amitriptyline and its metabolites nortriptyline, 10-hydroxyamitriptyline, and 10-hydroxynortriptyline, method for determination of, in human plasma using stable isotope dilution and gas chromatography–chemical ionization mass spectrometry (GC-CIMS) (Garland et al), 844
Ammonium chloride, treatment of alkalosis with; case report (Warren et al), 624
Anesthetic activity, local, of propranolol; effect on glucose-stimulated insulin release (Myers and Hope-Gill), 303
Animal self-administration results, similarity between evaluations of subjective effects and; opioids (Griffiths and Balster), 611
Announcements, 878
Antibiotic efficacy in acute bacterial meningitis, assessment of (Beam and Allen), 199
Antibodies, antinuclear, development of, during acebutolol therapy (Cody et al), 800
Anticholinergic, non-, drug overdose, physostigmine in coma due to (Nattel et al), 96
Antinuclear antibodies, development of, during acebutolol therapy (Cody et al), 800
Antipyrine elimination as indicator of metabolism of drugs and carcinogens in man (Kalamegham et al), 67
and phenacetin, metabolism of, stimulatory effect of brussels sprouts and cabbage on (Pantuck et al), 88
phenobarbital, and rifampicin, effect of enzyme induction on plasma lipids using (Ohnhaus et al), 591
Arrhythmias, supraventricular, acebutolol in (Aronow et al), 149
Arrhythmic, anti-, therapy, long-term, with *N*-acetylprocainamide (Lertora et al), 273
Arthritis, rheumatoid, pirprofen and aspirin in treatment of (Davis et al), 618
Aspirin Myocardial Infarction Study and Coronary Drug Project, recruitment in (Schoenberger), 681



January, pp. 1-130; February, pp. 131-256; March, pp. 257-380; April, pp. 381-492; May (Part 1), pp. 493-628; May (Part 2), pp. 629-766; June, pp. 767-896.

Aspirin—Cont'd
and pirprofen in treatment of rheumatoid arthritis (Davis et al), 618
Associates of Clinical Pharmacology, meeting program of, Third Annual Meeting, March 22-24, 1979, Crown Center Hotel, Kansas City, Mo., 130
Asthmatic patients, aerosol fenoterol by intermittent positive pressure breathing in (Ruffin et al), 821
effects of beta adrenoreceptor antagonist drugs on airways of (Ruffin et al), 536
Atenolol and chlorthalidone on blood pressure, heart rate, and plasma renin activity in hypertension (Teeuw et al), 294
kinetics and absolute bioavailability of (Mason et al), 408
and three nonselective beta blockers in hypertension (Waal-Manning), 8
Azosemide, "loop" diuretic, and furosemide (Brater et al), 435
renal sites of action of (Brater), 428

*B*

Beta adrenoreceptor antagonist drugs, selectivity of, assessed by histamine bronchial provocation (Ruffin et al), 536
blockade in hypertension, indoramin and prazosin as adjuncts to (Stokes et al)
after single and divided doses of penbutolol (Müller et al), 528
blockers, three nonselective, in hypertension, and atenolol (Waal-Manning), 8
receptor blockade, adrenergic, of alprenolol, contribution of 4-hydroxy-alprenolol to (Collste et al), 416
Biliary, non-, mechanism, gastrointestinal excretion of chlordecone, evidence for (Boylan et al), 579
Bioavailability, absolute, and kinetics of atenolol (Mason et al), 408
and kinetic parameters of cefadroxil (Cutler et al), 514
Biologic logic, scientific standards vs. statistical associations and, in analysis of causation (Feinstein), 481 (Clinical biostatistics)
Biostatistics, clinical. XLVI. What are the criteria for criteria? (Feinstein), 108
XLVII. Scientific standards vs. statistical associations and biologic logic in analysis of causation (Feinstein), 481
Biotransformation and elimination of digoxin with normal and minimal renal function (Gault et al), 499
Blood collection techniques, heparin and quinidine protein binding (Kessler et al), 204
flow, adipose tissue, and insulin disappearance from subcutaneous tissue (Kølendorf et al), 598
Blood flow—Cont'd
total hepatic, and shunting in chronic liver disease, noninvasive kinetic approach to—a hypothesis (McLean et al), 161
levels, diazepam, and protein binding in acute alcohol withdrawal (Pond et al), 832
Bolus compared with diazoxide infusion in severe hypertension and hypertensive crisis (Thien et al), 795
Books received, 256, 628
Brain tissue penetration; its significance for therapy of meningitis (Field et al), 199
Bromocriptine inhibits norepinephrine release (Ziegler et al), 137
Bronchial provocation, histamine, selectivity of beta adrenoreceptor antagonist drugs assessed by (Ruffin et al), 536
Brussels sprouts and cabbage, stimulatory effect of, on human drug metabolism (Pantuck et al), 88
Burned patients, urinary excretion of D-glucaric acid by (Ciaccio and Fruncillo), 340

*C*

Cabbage and brussels sprouts, stimulatory effect of, on human drug metabolism (Pantuck et al), 88
Caffeine metabolism in newborn (Aldridge et al), 447
Calcium carbimide–ethanol interaction; effects of ethanol dose (Brien et al), 454
Cancer, anti-, agent, new; kinetics of gallium nitrate (Hall et al), 82
Cannulas, indwelling heparinized (heparin lock), for sampling, altered drug binding due to use of (Wood et al), 103
γ-Carboxyglutamate excretion and warfarin therapy (Levy and Lian), 562
Carcinogens, metabolism of drugs and, in man; antipyrine elimination as indicator (Kalamegham et al), 67
Cardiac output in hypertension, effect of alpha-methyldopa on (Safar et al), 266
Cardioselectivity and acute hemodynamic effects of acebutolol, practolol, and propranolol (Wollam et al), 813
Cardiovascular effects of intravenous delta-9-tetrahydrocannabinol; autonomic nervous mechanisms (Benowitz et al), 440
response to severe hypotensive stress, effect of disulfiram on (Rogers et al), 469
Causation, analysis of, scientific standards vs. statistical associations and biologic logic in (Feinstein), 481 (Clinical biostatistics)
Cefadroxil kinetics in patients with renal insufficiency (Cutler et al), 514

Cephaloridine and cephapirin, renal excretion of; evidence for saturable tubular reabsorption (Arvidsson et al), 870
Cephapirin and cephaloridine, renal excretion of; evidence for saturable tubular reabsorption (Arvidsson et al), 870
Chemical ionization mass spectrometry, gas chromatography–, (GC-CIMS), method for determination of amitriptyline and its metabolites nortriptyline, 10-hydroxyamitriptyline, and 10-hydroxynortriptyline in human plasma using stable isotope dilution and (Garland et al), 844
Chlordecone, excretion of, by gastrointestinal tract; evidence for nonbiliary mechanism (Boylan et al), 579
Chlordiazepoxide, disposition of; sex differences and effects of oral contraceptives (Roberts et al), 826
Chloroquine serum concentration and side effects; evidence for dose-dependent kinetics (Frisk-Holmberg et al), 345
Chlorpromazine, inhibition of propranolol metabolism by (Vestal et al), 19
Chlorthalidone and atenolol, effect of, on blood pressure, heart rate, and plasma renin activity in hypertension (Teeuw et al), 294
  dose-dependent urinary excretion of (Fleuren et al), 806
  in hypertension, metoprolol with and without (Kubik et al), 25
Cigarette(s), effect of pH and urine flow on urinary nicotine excretion after smoking (Matsukura et al), 549
  smoking, daily, and cotinine excretion in habituated smokers (Matsukura et al), 555
Cirrhosis of liver, furosemide-induced adverse reactions in (Naranjo et al), 154
Clinic(s) monitoring, aspects of, in large-scale multiclinic trials (Mowery and Williams), 717
  multi-, trials, external monitoring in; applications from ophthalmologic studies (Ferris and Ederer), 720
    large-scale, aspects of clinic monitoring in (Mowery and Williams), 717
  patient and study management at; internal monitoring (Evans), 712
Clinical biostatistics. XLVI. What are the criteria for criteria? (Feinstein), 108
    XLVII. Scientific standards vs. statistical associations and biologic logic in analysis of causation (Feinstein), 481
  data, framework for quality assurance of (Williams), 700
  investigator, publications and promotions for (Relman), 673
Clinical Biostatistics—Cont'd
  Pharmacology, Associates of, meeting program of, Third Annual Meeting, March 22-24, 1979, Crown Center Hotel, Kansas City, Mo., 130
    and Therapeutics, American Society for, abstracts of papers, Eightieth Annual Meeting, March 21-23, 1979, Crown Center Hotel, Kansas City, Mo., 211
    meeting program of, Eightieth Annual Meeting, March 21-23, 1979, Crown Center Hotel, Kansas City, Mo., 118
    message from president of—come to Kansas City March 21-23, 1979, 117
    notes of, 380, 492, 877
  trial(s), ethical considerations in (Levine and Lebacqz), 728
    investigators, effective, and adequate incentives (Stamler), 666
    large, proposed mechanism and set of criteria for evaluation of scientific contribution of individual investigators in collaborative studies, including (Stamler), 671 (Appendix)
    long-term, terminating (Klimt and Canner), 641
    methodology, problems in publication of (Lasagna), 751
      retrieving information on (Schoolman), 758
    terminating—ethical problem (Meier), 633
    university-based scientists associated with, problems of (Remington), 662
Clonidine, antihypertensive effects of (Lilja et al), 864
Clotting time as factor in biologic half-life of heparin (McAvoy), 372
Coagulant, anti-, activity and kinetics of elimination of single dose of warfarin, effect of naproxen on (Slattery et al), 51
    and steady-state serum concentration of warfarin, effect of naproxen on (Jain et al), 61
  therapy, warfarin, effect of warfarin on γ-carboxyglutamate excretion in urine as method of monitoring (Levy and Lian), 562
Cocaine metabolism; cocaine and norcocaine hydrolysis by liver and serum esterases (Stewart et al), 464
Coma due to ammonium chloride; case report (Warren et al), 624
Communications, improved, case for; methodology (Meinert and Hawkins), 754
  problems of omission in (Mosteller), 761
Compliance of patients with medication (Moulding), 131 (Commentary)
Congestive heart failure, influence of, on prazosin kinetics (Jaillon et al), 790
Contraceptive(s), oral, effects of, sex differences and; disposition of chlordiazepoxide (Roberts et al), 826

Contraceptive(s), oral—Cont'd
steroids (norethindrone), inhibition of hepatic drug metabolism by (Field et al), 196
Coronary Drug Project and Aspirin Myocardial Infarction Study, recruitment in (Schoenberger), 681
Prevention Trial, LRC (Benedict), 685
Primary Prevention Trial, recruitment for (Agras and Marshall), 688
Cotinine excretion and daily cigarette smoking in habituated smokers (Matsukura et al), 555
Creatinine, endogenous "true," in normal subjects, saliva levels of (Chiou and Pu), 777
Criteria, set of, and proposed mechanism for evaluation of scientific contribution of individual investigators in collaborative studies, including large clinical trials (Stamler), 671 (Appendix)
what are criteria for? (Feinstein), 108 (Clinical biostatistics)

*D*

Data, clinical, framework for quality assurance of (Williams), 700
DCTQ, new PNMT inhibitor, studies with (Dubb et al), 837
Delta-9-tetrahydrocannabinol, intravenous, cardiovascular effects of; autonomic nervous mechanisms (Benowitz et al), 440
Desmethylimipramine and imipramine plasma concentrations, steady-state, prediction of, from single-dose data (Brunswick et al), 605
Diagnostic standardization (Kahn), 703
Diazepam kinetics in acute alcohol withdrawal (Pond et al), 832
Diazoxide infusion in severe hypertension and hypertensive crisis (Thien et al), 795
Dichloroallyl lawsone (McKelvey et al), 586
*cis*-Dichlorodiammineplatinum, kinetics of (Gormley et al), 351
Digoxin, biotransformation and elimination of, with normal and minimal renal function (Gault et al), 499
in elderly; pharmacokinetic consequences of old age (Cusack et al), 772
Disulfiram, effect of, on adrenergic function (Rogers et al), 469
Diuretic, clonidine with, antihypertensive effects of (Lilja et al), 864
"loop," (azosemide) and furosemide (Brater et al), 435
Dosage regimen for dichloroallyl lawsone (McKelvey et al), 586
Dose(s), single and divided, of penbutolol (Müller et al), 528
Dose(s), single—Cont'd
data, prediction of steady-state imipramine and desmethylimipramine plasma concentrations from (Brunswick et al), 605
Dose-dependent prednisolone kinetics (Tanner et al), 571
urinary excretion of chlorthalidone (Fleuren et al), 806
Drug, Coronary, Project and Aspirin Myocardial Infarction Study, recruitment in (Schoenberger), 681
reactions, adverse, and diseases, scale for assessing severity of (Tallarida et al), 381 (Commentary)
reactions, adverse, judgments of trained observers on (Blanc et al), 493
-related transient dyskinesias (Osifo), 767 (Commentary)
Dynamics and kinetics, drug, simultaneous modeling of; application to *d*-tubocurarine (Sheiner et al), 358
Dyskinesias, transient, drug-related (Osifo), 767 (Commentary)

*E*

Elderly, digoxin in; pharmacokinetic consequences of old age (Cusack et al), 772
Enzyme induction, effect of, on plasma lipids using antipyrine, phenobarbital, and rifampicin (Ohnhaus et al), 591
Ethanol dose, effects of; calcium carbimide–ethanol interaction (Brien et al), 454
Ethical considerations in clinical trials (Levine and Lebacqz), 728
problem—terminating clinical trial (Meier), 633
Evaluation of scientific contribution of individual investigators in collaborative studies, including large clinical trials, proposed mechanism and set of criteria for (Stamler), 671 (Appendix)
Exercise-induced tachycardia, effect of alprenolol and 4-hydroxy-alprenolol on, due to pentobarbital (Collste et al), 423

*F*

Fenoterol, aerosol, by intermittent positive pressure breathing in asthmatic patients (Ruffin et al), 821
Flurazepam and triazolam, comparative study of; methodology for demonstrating sustained efficacy of hypnotics (Sundaresan et al), 391
Food, effect of, on kinetics of 8-methoxsalen (Ehrsson et al), 167
Furesemide and azosemide, "loop" diuretic (Brater et al), 435
-induced adverse reactions in cirrhosis of liver (Naranjo et al), 154

*G*

Gallium nitrate, kinetics of; new anticancer agent (Hall et al), 82
Gallstone Study, National Cooperative, recruitment for (Croke), 691
Gas chromatography–chemical ionization mass spectrometry (GC-CIMS), method for determination of amitriptyline and its metabolites nortriptyline, 10-hydroxyamitriptyline, and 10-hydroxynortriptyline in human plasma using stable isotope dilution and (Garland et al), 844
Gastrointestinal tract, excretion of chlordecone by; evidence for nonbiliary mechanism (Boylan et al), 579
D-Glucaric acid, urinary excretion of, by severely burned patients (Ciaccio and Fruncillo), 340
Glucose-stimulated insulin release, effect of *d*- and *dl*-propanolol on (Myers and Hope-Gill), 303
Guanfacine kinetics in patients with hypertension (Weiss et al), 283

*H*

Half-life, biologic, of heparin (McAvoy), 372
Heart failure, acute and chronic, isosorbide dinitrate in (Venkataraman et al), 43
  congestive, influence of, on prazosin kinetics (Jaillon et al), 790
Hemodynamic effects, acute, and cardioselectivity of acebutolol, practolol, and propranolol (Wollam et al), 813
  of sublingual isosorbide dinitrate (Venkataraman et al), 43
Henle's loop, solute transport in (Brater), 428
Heparin, biologic half-life of (McAvoy), 372
  lock (indwelling heparinized cannulas) for sampling, altered drug binding due to use of (Wood et al), 103
  and quinidine protein binding; blood collection techniques (Kessler et al), 204
Hepatic blood flow, total, and shunting in chronic liver disease, noninvasive kinetic approach to estimation of—a hypothesis (McLean et al), 161
  capacity for drug metabolism, effect of urinary D-glucaric acid on, in severely burned patients (Ciaccio and Fruncillo), 340
  drug metabolism, inhibition of, by norethindrone (Field et al), 196
Histamine bronchial provocation, selectivity of beta adrenoreceptor antagonist drugs assessed by (Ruffin et al), 530
Homeostasis, water and salt, effect of indomethacin on (Brater), 322
Hydrochlorothiazide, site of action of, similar to xipamide (Gold and Viljoen), 522
Hydrochlorothiazide—Cont'd
  and spironolactone in hypertension (Schrijver and Weinberger), 33
Hydrolysis of norcocaine and cocaine by liver and serum esterases; cocaine metabolism (Stewart et al), 464
4-Hydroxy-alprenolol and alprenolol, effect and plasma levels of, influence of pentobarbital on (Collste et al), 423
  contribution of, to adrenergic beta receptor blockage of alprenolol (Collste et al), 416
10-Hydroxyamitriptyline, nortriptyline, and 10-hydroxynortriptyline, metabolites of amitriptyline, method for determination of amitriptyline and, in human plasma using stable isotope dilution and gas chromatography–chemical ionization mass spectrometry (GC-CIMS) (Garland et al)
10-Hydroxynortriptyline, nortriptyline, and 10-hydroxyamitriptyline, metabolites of amitriptyline, method for determination of amitriptyline and, in human plasma using stable isotope dilution and gas chromatography–chemical ionization mass spectrometry (GC-CIMS) (Garland et al), 844
Hyperlipoproteinemia, effect of; binding of imipramine to plasma proteins (Danon and Chen), 316
Hypertension, atenolol and three nonselective beta blockers in (Waal-Manning), 8
  blood pressure, heart rate, and plasma renin activity in, atenolol and chlorthalidone on (Teeuw et al), 294
  cardiac output in, effect of alpha-methylodopa on (Safar et al), 266
  hydrochlorothiazide and spironolactone in (Schrijver and Weinberger), 33
  indoramin and prazosin as adjuncts to beta adrenoreceptor blockade in (Stokes et al), 783
  lowered blood pressure in, due to inhibition of norepinephrine release by bromocriptine (Ziegler et al), 137
  metoprolol with and without chlorthalidone in (Kubik et al), 25
  patients with, guanfacine kinetics in (Weiss et al), 283
  prazosin in, with and without methyldopa (Kochar et al), 143
  primary, once-daily metoprolol in (Karlberg et al), 399
  pulmonary, in chronic obstructive pulmonary disease, effects of isosorbide dinitrate on (Danahy et al), 541
  severe, and hypertensive crisis, diazoxide infusion in (Thien et al), 795

Hypertensive, anti-, effects of clonidine (Lilja et al), 864
crisis and severe hypertension, diazoxide infusion in (Thien et al), 795
Hypnotics, sustained efficacy of, methodology for demonstrating; comparative study of triazolam and flurazepam (Sundaresan et al), 391
Hypotensive stress, cardiovascular response to, effect of disulfiram on (Rogers et al), 469
Hypothermia, effects of, on propranolol kinetics (McAllister et al), 1

*I*

Imipramine, binding of, to plasma proteins; effect of hyperlipoproteinemia (Danon and Chen), 316
and desmethylimipramine plasma concentrations, steady-state, prediction of, from single-dose data (Brunswick et al), 605
Immunologic status and myocardial function, effect of *N*-acetylprocainamide on (Lertora et al), 273
Incentives, adequate, and effective clinical trials investigators (Stamler), 666
Indomethacin, effect of, on salt and water homeostasis (Brater), 322
Indoramin and prazosin as adjuncts to beta adrenoreceptor blockade in hypertension (Stokes et al), 783
Inhibitor, PNMT, studies with (Dubb et al), 837
Insulin disappearance from subcutaneous tissue, adipose tissue blood flow and (Kølendorf et al), 598
release, glucose-stimulated, effect of *d*- and *dl*-propranolol on (Myers and Hope-Gill), 303
Intermittent positive pressure breathing, aerosol fenoterol by, in asthmatic patients (Ruffin et al), 821
Investigator(s), clinical, publications and promotions for (Relman), 673
effective, of clinical trials, and adequate incentives (Stamler), 666
Isosorbide dinitrate in acute and chronic heart failure (Venkataraman et al), 43
effects of, on pulmonary hypertension in chronic obstructive pulmonary disease (Danahy et al), 541
Isotope dilution, stable, and gas chromatography–chemical ionization mass spectrometry (GC-CIMS), method for determination of amitriptyline and its metabolites nortriptyline, 10-hydroxyamitriptyline, and 10-hydroxynortriptyline in human plasma using (Garland et al), 844

*K*

Kinetic(s) and absolute bioavailability of atenolol (Mason et al), 408
acetaminophen, in acutely poisoned patients (Slattery and Levy), 184
approach, noninvasive, to estimation of total hepatic blood flow and shunting in chronic liver disease—a hypothesis (McLean et al), 161
of cefadroxil in patients with renal insufficiency (Cutler et al), 514
of cephaloridines (Arvidsson et al), 870
diazepam, in acute alcohol withdrawal (Pond et al), 832
of *cis*-dichlorodiammineplatinum (Gormley et al), 351
dose-dependent, evidence for; chloroquine serum concentration and side effects (Frisk-Holmberg), 345
and dynamics, drug, simultaneous modeling of; application to *d*-tubocurarine (Sheiner et al), 358
of elimination and anticoagulant activity of single dose of warfarin, effect of naproxen on (Slattery et al), 51
of gallium nitrate, new anticancer agent (Hall et al), 82
, guanfacine, in patients with hypertension (Weiss et al), 283
and metabolic parameters and safe dosage regimen for dichloroallyl lawsone (McKelvey et al), 586
of 8-methoxsalen, effect of food on (Ehrsson et al), 167
prazosin, influence of congestive heart failure on (Jaillon et al), 790
of prednisolone, dose-dependent (Tanner et al), 571
propranolol, effects of hypothermia on (McAllister et al), 1
sulfamethazine, mechanisms of nonlinear disposition of (du Souich et al), 172
warfarin, effect of smoking on (Bachmann et al), 309

*L*

Lipids, plasma, effect of enzyme induction on, using antipyrine, phenobarbital, and rifampicin (Ohnhaus et al), 591
Lipoprotein binding of imipramine due to hyperlipoproteinemia (Danon and Chen), 316
Liver, cirrhosis of, furosemide-induced adverse reactions in (Naranjo et al), 154
disease, chronic, noninvasive kinetic approach to estimation of total hepatic blood flow and shunting in—a hypothesis (McLean et al), 161

Liver—Cont'd
and serum esterases, cocaine and norcocaine hydrolysis by; cocaine metabolism (Stewart et al), 464
Logic, biologic, scientific standards vs. statistical associations and, in analysis of causation (Feinstein), 481 (Clinical biostatistics)

*M*

Magnesium trisilicate, effect of, on nitrofurantoin absorption (Naggar and Khalil), 857
Malarial, anti-, drugs, and transient dyskinesias (Osifo), 767 (Commentary)
Mass spectrometry, gas chromatography–chemical ionization, (GC-CIMS), method for determination of amitriptyline and its metabolites nortriptyline, 10-hydroxyamitriptyline, and 10-hydroxynortriptyline in human plasma using stable isotope dilution and (Garland et al), 844
Measurement of (numerical scale for assessing) diseases and adverse drug reactions (Tallarida et al), 381 (Commentary)
Medication monitor, unrealized potential of (Moulding), 131 (Commentary)
packaging; simple solutions to nonadherence problems? (Rudd), 257 (Commentary)
Meningitis, acute bacterial, assessment of antibiotic efficacy in (Beam and Allen), 199
Metabolic and kinetic parameters and safe dosage regimen for dichloroallyl lawsone (McKelvey et al), 586
Metabolism of caffeine in newborn (Aldridge et al), 447
of cocaine; cocaine and norcocaine hydrolysis by liver and serum esterases (Stewart et al), 464
of drug(s) and carcinogens in man; antipyrine elimination as indicator (Kalamegham et al), 67
hepatic capacity for, effect of urinary D-glucaric acid on (Ciaccio and Fruncillo), 340
human, stimulatory effect of brussels sprouts and cabbage on (Pantuck et al), 88
of oxazepam and its placental passage in mother and newborn (Tomson et al), 74
propranolol, inhibition of, by chlorpromazine (Vestal et al), 19
Methodology; case for improved communications (Meinert and Hawkins), 754
clinical trial, problems in publication of (Lasagna), 751
retrieving information on (Schoolman), 758
Methoxsalen, 8-, effect of food on kinetics of (Ehrrson et al), 167
serum concentration and phototoxic effect of, in patients with psoriasis (Swanbeck et al), 478
Metoprolol, once-daily, in primary hypertension (Karlberg et al), 399
and timolol, effects of, on airways of asthmatic patients (Ruffin et al), 536
with and without chlorthalidone in hypertension (Kubik et al), 25
Methyldopa, alpha-, effect of, on cardiac output in hypertension (Safar et al), 266
prazosin with and without, in hypertension (Kochar et al), 143
Modeling, simultaneous, of pharmacokinetics and pharmacodynamics; application to *d*-tubocurarine (Sheiner et al), 358
Monitor, medication, unrealized potential of (Moulding), 131 (Commentary)
Monitoring, clinic, aspects of, in large-scale multiclinic trials (Mowery and Williams), 717
of drugs using judgments of trained observers (Blanc et al), 493
external, in multiclinic trials; applications from ophthalmologic studies (Ferris and Ederer), 720
internal; patient and study management at clinics (Evans), 712
of warfarin anticoagulation therapy, effect of warfarin on γ-carboxyglutamate excretion in urine as method of (Levy and Lian), 562
Mother in labor and newborn, metabolism of oxazepam and its placental passage in (Tomson et al), 74
Myocardial function and immunologic status, effect of *N*-acetylprocainamide on (Lertora et al), 273
Infarction Study, Aspirin, and Coronary Drug Project, recruitment in (Schoenberger), 681

*N*

Naproxen, effect of, on kinetics of elimination and anticoagulant activity of single dose of warfarin (Slattery et al), 51
on steady-state serum concentration and anticoagulant activity of warfarin (Jain et al), 61
Nervous mechanisms, autonomic; cardiovascular effects of intravenous delta-9-tetrahydrocannabinol (Benowitz et al), 440
Newborn, caffeine metabolism in (Aldridge et al), 447
and mother, metabolism of oxazepam and its placental passage in (Tomson et al), 74
Nitrofurantoin absorption, effect of magnesium trisilicate on (Naggar and Khalil), 857
Nonadherence problems, simple solutions to; medication packaging (Rudd), 257 (Commentary)

Nonlinear disposition kinetics of sulfamethazine, mechanisms of (du Souich et al), 172
Norcocaine and cocaine hydrolysis by liver and serum esterases; cocaine metabolism (Stewart et al), 464
Norepinephrine, excretion of, effect of disulfiram on (Rogers et al), 469
release, inhibited by bromocriptine (Ziegler et al), 137
Norethindrone, inhibition of hepatic drug metabolism by (Field et al), 196
Nortriptyline, 10-hydroxyamitriptyline, and 10-hydroxynortriptyline, metabolites of amitriptyline, method for determination of amitriptyline and, in human plasma using stable isotope dilution and gas chromatography–chemical ionization mass spectrometry (GC-CIMS) (Garland et al), 844

*O*

Observers, trained, judgments of, on adverse drug reactions (Blanc et al), 493
Ophthalmologic studies, applications from; external monitoring in multiclinic trials (Ferris and Ederer), 720
Opioids; similarity between evaluations of subjective effects and animal self-administration results (Griffiths and Balster), 611
Organoplatinum molecule in man, kinetics of (Gormley et al), 351
Overdose, drug, physostigmine in coma due to (Nattel et al), 96
Oxazepam, placental passage of, and its metabolism in mother and newborn (Tomson et al), 74

*P*

Packaging, medication; simple solutions to nonadherence problems? (Rudd), 257 (Commentary)
Patient and study management at clinics; internal monitoring (Evans), 712
Penbutolol, single and divided doses of (Müller et al), 528
Pentobarbital, influence of, on effect and plasma levels of alprenolol and 4-hydroxy-alprenolol (Collste et al), 423
pH and urine flow, effect of, on urinary nicotine excretion after smoking cigarettes (Matsukura et al), 549
Pharmacodynamics and pharmacokinetics, simultaneous modeling of; application to *d*-tubocurarine (Sheiner et al), 358
Pharmacokinetic(s) consequences of old age; digoxin in elderly (Cusack et al), 772
and pharmacodynamics, simultaneous modeling of; application to *d*-tubocurarine (Sheiner et al), 358
Pharmacology, Clinical, Associates of, meeting program of, Third Annual Meeting, March 22-24, 1979, Crown Center Hotel, Kansas City, Mo., 130
and Therapeutics, Clinical, American Society for, abstracts of papers, Eightieth Annual Meeting, March 21-23, 1979, Crown Center Hotel, Kansas City, Mo., 211
meeting program of, Eightieth Annual Meeting, March 21-23, 1979, Crown Center Hotel, Kansas City, Mo., 118
message from president—come to Kansas City March 21-23, 1979, 117
notes of, 380, 492, 877
Phenacetin and antipyrine, metabolism of, stimulatory effect of brussels sprouts and cabbage on (Pantuck et al), 88
Phenobarbital, antipyrine, and rifampicin, effect of enzyme induction on plasma lipids using (Ohnhaus et al), 591
Phosphate excretion and urinary pH, effect of piretanide on (Teredesai and Puschett), 331
Phototoxic effect and serum concentration of methoxsalen in patients with psoriasis (Swanbeck et al), 478
Physostigmine in coma due to drug overdose (Nattel et al), 96
Piretanide, acute effects of, in normal subjects (Teredesai and Puschett), 331
Pirprofen and aspirin in treatment of rheumatoid arthritis (Davis et al), 618
Placental passage of oxazepam and its metabolism in mother and newborn (Tomson et al), 74
Plasma binding of propranolol, effect of heparin lock for blood sampling on (Wood et al), 103
concentrations, steady-state imipramine and desmethylimipramine, prediction of, from single-dose data (Brunswick et al), 605
human, method for determination of amitriptyline and its metabolites nortriptyline, 10-hydroxyamitriptyline, and 10-hydroxynortriptyline in, using stable isotope dilution and gas chromatography–chemical ionization mass spectrometry (GC-CIMS) (Garland et al), 844
levels and effect of alprenolol and 4-hydroxy-alprenolol, influence of pentobarbital on (Collste et al), 423
lipids, effect of enzyme induction on, using antipyrine, phenobarbital, and rifampicin (Ohnhaus et al), 591
protein(s), binding of imipramine to; effect of hyperlipoproteinemia (Danon and Chen), 316
quinidine binding to, effects of heparin on (Kessler et al), 204

Plasma—Cont'd
renin activity and metoprolol concentration, effect of metoprolol on (Karlberg et al), 399
and serum levels and salivary creatinine (Chiou and Pu), 777
PNMT inhibitor, studies with (Dubb et al), 837
Poisoned patients, acetaminophen kinetics in (Slattery and Levy), 184
Practolol, acebutolol, and propranolol, acute hemodynamic effects and cardioselectivity of (Wollam et al), 813
Prazosin in hypertension with and without methyldopa (Kochar et al), 143
and indoramin as adjuncts to beta adrenoreceptor blockade in hypertension (Stokes et al), 783
kinetics, influence of congestive heart failure on (Jaillon et al), 790
Prednisolone kinetics, dose-dependent (Tanner et al), 571
Procainamide, advantages of *N*-acetylprocainamide over, in long-term therapy (Lertora et al), 273
Promotions, publications and, for clinical investigator (Relman), 673
Propranolol, acebutolol, and practolol, acute hemodynamic effects and cardioselectivity of (Wollam et al), 813
*d*- and *dl*-, effect of, on glucose-stimulated insulin release (Myers and Hope-Gill), 303
kinetics, effects of hypothermia on (McAllister et al), 1
metabolism, inhibition of, by chlorpromazine (Vestal et al), 19
plasma binding of, effect of heparin lock for blood sampling on (Wood et al), 103
Prostaglandins, modulation of renal sodium excretion by (Brater), 322
Protein binding and diazepam blood levels in acute alcohol withdrawal (Pond et al), 832
Psoriasis, patients with, serum concentration and phototoxic effect of methoxsalen in (Swanbeck et al), 478
Publication(s) of clinical trial methodology, problems in (Lasagna), 751
and promotions for clinical investigator (Relman), 673
Pulmonary hypertension in chronic obstructive pulmonary disease, effects of isosorbide dinitrate on (Danahy et al), 541

*Q*

Quinidine protein binding and heparin; blood collection techniques (Kessler et al), 204

*R*

Reactions, adverse drug, and diseases, scale for assessing severity of (Tallarida et al), 381 (Commentary)
Reactions, adverse drug—Cont'd
judgments of trained observers on (Blanc et al), 493
Recruitment in Coronary Drug Project and Aspirin Myocardial Infarction study (Schoenberger), 681
Primary Prevention Trial (Agras and Marshall), 688
for National Cooperative Gallstone Study (Croke), 691
problems and solutions (Prout), 695
Renal action of xipamide, site of (Gold and Viljoen), 522
excretion of cephapirin and cephaloridine; evidence for saturable tubular reabsorption (Arvidsson et al), 870
function, normal and minimal, biotransformation and elimination of digoxin with (Gault et al), 499
insufficiency, cefadroxil kinetics in patients with (Cutler et al), 514
sites of action of azosemide (Brater), 428
Rheumatoid arthritis, pirprofen and aspirin in treatment of (Davis et al), 618
Rifampicin, antipyrine, and phenobarbital, effect of enzyme induction on plasma lipids using (Ohnhaus et al), 591

*S*

Saliva levels of endogenous "true" creatinine in normal subjects (Chiou and Pu), 777
Scientific standards vs. statistical associations and biologic logic in analysis of causation (Feinstein), 481 (Clinical biostatistics)
Serum concentration, chloroquine, and side effects; evidence for dose-dependent kinetics (Frisk-Holmberg et al), 345
and phototoxic effect of methoxsalen in patients with psoriasis (Swanbeck et al), 478
steady-state, and anticoagulant activity of warfarin, effect of naproxen on (Jain et al), 61
esterases, liver and, hydrolysis of cocaine and norcocaine by; cocaine metabolism (Stewart et al), 464
and plasma levels and salivary creatinine (Chiou and Pu), 777
Sex differences and effects of oral contraceptives; disposition of chlordiazepoxide (Roberts et al), 826
hormones, effect of, on drug metabolism (Field et al), 196
Shunting and total hepatic blood flow in chronic liver disease, noninvasive kinetic approach to estimation of—a hypothesis (McLean et al), 161
Sites, renal, of action of azosemide (Brater), 428
Smoking cigarettes, effect of pH and urine flow on urinary nicotine excretion after (Matsukura et al), 549

Smoking—Cont'd
cotinine excretion in urine as indicator of (Matsukura et al), 555
and warfarin disposition (Bachmann et al), 309
Sodium excretion, renal, modulation of, by prostaglandins (Brater), 322
Spironolactone and hydrochlorothiazide in hypertension (Schrijver and Weinberger), 33
Standardization, diagnostic (Kahn), 703
Statistical associations vs. scientific standards and biologic logic in analysis of causation (Feinstein), 481 (Clinical biostatistics)
Study and patient management at clinics; internal monitoring (Evans), 712
Sulfamethazine kinetics, mechanisms of nonlinear dispotisition of (du Souich et al), 172

*T*

Tachycardia, exercise-induced, effect of alprenolol and 4-hydroxy-alprenolol on, due to pentobarbital (Collste et al), 423
Therapeutics, American Society for Clinical Pharmacology and, abstracts of papers, Eighteth Annual Meeting, March 21-23, 1979, Crown Center Hotel, Kansas City, Mo., 211
meeting program of, Eighteth Annual Meeting, March 21-23, 1979, Crown Center Hotel, Kansas City, Mo., 118
message from president of—come to Kansas City March 21-23, 1979, 117
notes of, 380, 492, 877
Timolol and metoprolol, effects of, on airways of asthmatic patients (Ruffin et al), 536
Tissue, adipose, blood flow and insulin disappearance from subcutaneous tissue (Kølendorf et al), 598
Trial(s), clinical, effective investigators of, and adequate incentives (Stamler), 666
ethical considerations in (Levine and Lebacqz), 728
long-term, terminating (Klimt and Canner), 641
methodology, problems in publication of (Lasagna), 751
retrieving information on (Schoolman), 758
terminating—ethical problem (Meier), 633
university-based scientists associated with, problems of (Remington), 662
Coronary Primary Prevention, recruitment for (Agras and Marshall), 688
large clinical, proposed mechanism and set of criteria for evaluation of scientific contribution of individual investigators in collaborative studies, including (Stamler), 671 (Appendix)
Trial(s)—Cont'd
large-scale multiclinic, aspects of clinic monitoring in (Mowery and Williams), 717
, LRC Coronary Prevention (Benedict), 685
Triazolam and flurazepam, comparative study of; methodology for demonstrating sustained efficacy of hypnotics (Sundaresan et al), 391
*d*-Tubocurarine, application of simultaneous modeling of pharmacokinetics and pharmacodynamics to (Sheiner et al), 358
Tubular reabsorption, saturable evidence for; renal excretion of cephapirin and cephaloridine (Arvidsson et al), 870
Tubule, distal convoluted, as site of renal action of xipamide (Gold and Viljoen), 522

*U*

Ultraviolet light therapy, effect of food on kinetics of 8-methoxsalen during (Ehrsson et al), 167
University-based scientists associated with clinical trials, problems of (Remington), 662
Urinary excretion, dose-dependent, of chlorthalidone (Fleuren et al), 806
of D-glucaric acid by severely burned patients (Ciaccio and Fruncillo), 340
pH and phosphate excretion, effect of piretanide on (Teredesai and Puschett), 331
Urine, excretion of nitrofurantoin in, effect of magnesium trisilicate on (Naggar and Khalil), 857
flow and pH, effect of, on urinary nicotine excretion after smoking cigarettes (Matsukura et al), 549

*V*

Ventricular, supra-, arrhythmias, acebutolol in (Aronow et al), 149

*W*

Warfarin disposition, smoking and (Bachmann et al), 309
effect of naproxen on steady-state serum concentration and anticoagulant activity of (Jain et al), 61
single dose of, effect of naproxen on kinetics of elimination and anticoagulant activity of (Slattery et al), 51
therapy and γ-carboxyglutamate excretion (Levy and Lian), 562

*X*

Xipamide, site of renal action of (Gold and Viljoen), 522